The Pediatric& SDH-Deficient GIST Consortium is committed to:
Build a Consortium
Create and Expand Clinical Trials
Involve Patient Advocacy Groups
Why a Pediatric & SDH-Deficient GIST Consortium?
There is a subset of GIST which specifically affects children and young adults with a resistant form of GIST for which the current battery of drugs are not particularly effective. Since the number of these types of patients is relatively small and the nature of this subset comparatively complex, progress finding effective treatment has been difficult.
Historically, most researchers with an interest in Pediatric & SDH-Deficient GIST worked independently from other GIST researchers, with each seeing very few of these rare disease patients. The National Institutes of Health (NIH) Pediatric and Wildtype GIST Clinic was established in 2008 with the support of advocacy organizations, to bring together clinicians and patients, to begin to better understand this rare disease. After 10 successful years, this program is at a crossroads, just at a time when no standard of care for this rare disease has been defined.
Based on this need, the Life Raft Group created and convened the inaugural Pediatric & SDH-Deficient GIST Research Symposium on July 14-15th at Life Fest 2018 in Miami. The goal of the symposium was to gather key clinicians/researchers to identify KIT-independent therapies for targeting SDH-Deficient tumors in order to improve patient outcomes.
An outgrowth of the symposium was the formation of the Pediatric & SDH-Deficient GIST Consortium. The aim of the consortium is to extend and sustain the work of the NIH Clinic and other research efforts, with the ultimate goal of finding a cure through global collaboration. As patients’ survival and quality of life are dramatically impacted by this disease, it is critically urgent that the leading Pediatric & SDH-Deficient GIST experts collaborate and share data and tissue, with the goal of finding successful targeted therapies that can help keep these patients alive.
Founders of The Pediatric & SDH-Deficient GIST Consortium Include Clinical/Research Partners:
- Christopher B. Weldon, MD, PhD, Boston Children’s Hospital
- Venkata Ramesh Bulusu, MD, Cambridge University Hospitals, UK
- Ruth Casey, PhD, Cambridge University Hospitals, UK
- Olivier Giger, MD, Cambridge University Hospital, UK
- Lee Helman, MD, Children’s Hospital Los Angeles
- Suzanne George, MD, Dana-Farber Cancer Institute
- Katherine Janeway, MD, Dana-Farber Cancer Institute
- Jonathan Keith Killian, MD, PhD, Foundation Medicine
- Margaret von Mehren, MD, Fox Chase Cancer Center
- Joshua Schiffman, MD, Huntsman Cancer Institute
- Michael P. LaQuaglia, MD, Memorial Sloan Kettering Cancer Center
- Jason Sicklick, MD, Moores Cancer Center, University of California, San Diego
- Fernanda Arnaldez, MD, National Cancer Institute
- Markku Martti Miettinen, MD, National Cancer Institute
- Karel Pacak, D.Sc., MD, PhD, National Institutes of Health
- Constantine Stratakis, MD, National Institutes of Health
- Michael Heinrich, MD, Oregon Health and Science University
- Alberto S. Pappo, MD, St. Jude Children’s Research Hospital
- Jonathan Trent, MD, Sylvester Comprehensive Cancer Center
- Eyal Gottlieb, MSc, PhD, Technion-Israel Institute of Technology
- Maria Pantaleo, MD, University of Bologna, Italy
- Sosipatros Boikos, MD, VCU Massey Cancer Center
Patient Advocacy Partners Include:
- Phyllis Gay, GIST Support International
- Dr. Victoria Bassett, GIST Support UK
- Jayne Bressington, GIST Support UK
- Becky Owens, SDH-RA Cancer Research Advocates
- Norman Scherzer, The Life Raft Group
- Sara Rothschild, MPH, The Life Raft Group
- Yu Wang, MB, PhD, The Life Raft Group